French Microbiome Therapy boosted by compound from major US Biotech

19/04/2016 - 3 minutes

Enterome, a leader in the European microbiome field, has struck a deal with US’ Vertex to develop novel small molecules with potential to treat inflammatory bowel diseases.

enterome_vertex_microbiome_bowelWith an impressive roll of partnerships and backed by the world-first Microbiome fund, Enterome is very well-positioned in hype field of the Microbiome.

We discussed Enterome’s differentiated strategy to turn microbiome research into medical therapies in an interview with CEO Pierre Belichard just this February.

Now, Enterome has entered an exclusive worldwide license agreement with Vertex Pharmaceuticals, one of the most well-established Biotechs – it even has a book about its history.

We don’t know how much Enterome paid for this deal, but it covers several novel small molecule for use in the treatment of inflammatory bowel diseases (IBD), including Crohn’s disease.

This new programme targets adherent-invasive Escherichia coli (AIEC), which Enterome has identified as a key bacterial species in triggering inflammation.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!